Efficacy, Safety, and Immunogenicity of DNA SARS-CoV-2 Vaccine (ZyCoV-D)
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
Lancet 2022 Apr 02;399(10332)1313-1321, A Khobragade, S Bhate, V Ramaiah, S Deshpande, K Giri, H Phophle, P Supe, I Godara, R Revanna, R Nagarkar, J Sanmukhani, A Dey, TMC Rajanathan, K Kansagra, P KoradiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.